Novavax Stock Review

by admin

If you’re interested in investing in biotechnology stocks, you should look into Novavax stock. The company is based in Gaithersburg, Maryland and is developing vaccines to combat serious infectious diseases. Its scientists have already developed experimental vaccines for influenza and respiratory syncytial virus. And it’s working on vaccines for Ebola and other emerging threats. Vaccines can prevent the spread of infectious diseases and protect people and the environment.

Novavax stock recently posted its second quarter earnings. The company reported a loss of $6.53 per share, a decline of almost 20% from its first-quarter profit. However, the company’s revenue was up 141% from last year. Analysts expect the company to generate $2.04 billion in revenue this year, which would be a record high. However, they aren’t recommending buying the stock based on the results of their estimates.

While the company has made significant progress in developing a vaccine to prevent influenza, the company has yet to see widespread market acceptance. This is despite the fact that the company received $89 million in funding from the Bill & Melinda Gates Foundation in 2015. Since that time, the company has had to cut its staff by almost a third. As a result, its stock has fallen 89% since February. But the stock’s recent rally was triggered by the news that the U.S. government approved a primary flu vaccine by Novavax.

A biotechnology company based in Gaithersburg, Maryland, Novavax develops vaccines to prevent and treat many serious diseases. The company’s vaccine candidates are designed to protect individuals against influenza, respiratory syncytial virus, and Ebola.

You may also like

Leave a Comment